➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Medtronic
Johnson and Johnson
Merck
Baxter
Colorcon
AstraZeneca

Last Updated: September 18, 2021

DrugPatentWatch Database Preview

Claims for Patent: 4,758,511

➤ Get the DrugPatentWatch Daily Briefing

« Back to Dashboard

Summary for Patent: 4,758,511
Title: CDNA clones coding for polypeptides exhibiting IGE binding factor activity
Abstract:Plasmid vectors are provided that carry complementary DNA (cDNA) clones coding for polypeptides exhibiting mammalian IgE binding factor activity. One of these clones contains an open reading frame consisting of 556 codons. The cDNA is derived from messenger RNA isolated from a rat/mouse T-cell hybridoma line. The cDNA was cloned by incorporation into a pcD plasmid vector. The plasmid vector also contains DNA segments from the SV40 virus, permitting expression of the cDNA to form a polypeptide having IgE potentiating activity after transfection into a mammalian host cell, such as monkey Cos7 cells.
Inventor(s): Martens; Christine L. (Menlo Park, CA), Moore; Kevin W. (San Bruno, CA), Ishizaka; Kimishige (Towson, MD), Huff; Thomas F. (Baltimore, MD)
Assignee: DNAX Research Institute of Molecular and Cellular Biology, Inc. (Palo Alto, CA) The Johns Hopkins University (Baltimore, MD)
Application Number:06/590,430
Patent Claims:1. A process for producing a polypeptide exhibiting mammalian IgE binding factor activity; said process comprising the steps of:

providing a vector comprising a nucleotide sequence coding for said polypeptide, wherein the nucleotide sequence is capable of being expresed by a host containing the vector and wherein the nucleotide sequence is the complementary DNA insert of a vector selected from the group consisting of 23B6p4.2, 23B56p8.3, 23B6p9.5, and 23B6p10.2;

incorporating the vector into the host; and

maintaining the vector-containing host under conditions suitable for expression of the nucleotide sequence into said polypeptide.

2. The process of claim 1 wherein the host is an organism transformed or transfected with the vector.

3. The process of claim 2 wherein the host is a eukaryotic cell.

4. The process of claim 1 wherein the vector comprises the nucleotide coding for said polypeptide linked to a second nucleotide sequence, wherein the second nucleotide sequence is capable of controlling expression of the nucleotide sequence coding for said polypeptide.

5. The process of claim 4 wherein the second nucleotide sequence comprises a promoter sequence which promotes express of the nucleotide sequence coding for said polypeptide.

6. The process of claim 4 wherein the host is a mammalian cell.

7. The process of claim 6 wherein the second nucleotide sequence comprises a promoter sequence, one or more intron sequences, an da polyadenylation sequence, whereby the nucleotide sequence coding for said polypeptide is transcribed, spliced and polyadenylated prior to translation in the mammalian cell.

8. The process of claim 7 wherein the promoter sequence is an SV40 virus early region promoter and the polyadenylation sequence is an SV40 virus late region polyadenylation sequence.

9. The process of claim 8 wherein the mammalian cell is a monkey Cos7 cell.

10. The process of claim 1 wherein said polypeptide includes a leader sequence.

11. The process of claim 1 wherein said host is a mammalian cell, and wherein said polypeptide is glycosylated and exhibits either IgE potentiating factor activity of IgE suppressive factor activity.

12. The process of claim 11 wherein said mammalian cell is selected so that said polypeptide exhibits IgE suppressive factor activity.

13. The process of claim 11 wherein said mammalian cell is selected so that said polypeptide exhibits IgE potentiating factor activity.

14. A replicable vector carrying a DNA sequence encoding for a polypeptide exhibiting IgE binding factor activity, said vector being selected from the group consisting of 23B6p4.2, 23B6p8.3, 23B6p9.5, and 23B6p10.2.

15. A nucleic acid selected from the group consisting of the inserts of vector 23B6p4.2, 23B6p8.3, 23B6p9.5, or 23B6p10.2.

16. A mammalian nucleic acid capable of encoding a polypeptide exhibiting IgE binding factor activity, the mammalian nucleic acid having a nucleotide sequence selected from the group consisting of: ##STR1##

Details for Patent 4,758,511

Applicant Tradename Biologic Ingredient Dosage Form BLA Number Approval Date Patent No. Assignee Estimated Patent Expiration Status Orphan Source
Schering INTRON A interferon alfa-2b VIAL 103132 001 1986-06-04 ⤷  Free Forever Trial DNAX Research Institute of Molecular and Cellular Biology, Inc. (Palo Alto, CA) The Johns Hopkins University (Baltimore, MD) 2039-02-26 RX search
Schering INTRON A interferon alfa-2b VIAL 103132 002 1986-06-04 ⤷  Free Forever Trial DNAX Research Institute of Molecular and Cellular Biology, Inc. (Palo Alto, CA) The Johns Hopkins University (Baltimore, MD) 2039-02-26 RX search
Schering INTRON A interferon alfa-2b VIAL 103132 003 1986-06-04 ⤷  Free Forever Trial DNAX Research Institute of Molecular and Cellular Biology, Inc. (Palo Alto, CA) The Johns Hopkins University (Baltimore, MD) 2039-02-26 RX search
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Number >Approval Date >Patent No. >Assignee >Estimated Patent Expiration >Status >Orphan >Source

International Patent Family for US Patent 4,758,511

Country Patent Number Estimated Expiration
Australia 3976385 ⤷  Free Forever Trial
Australia 594013 ⤷  Free Forever Trial
Denmark 117085 ⤷  Free Forever Trial
European Patent Office 0155192 ⤷  Free Forever Trial
Spain 8607392 ⤷  Free Forever Trial
Greece 850645 ⤷  Free Forever Trial
Hungary 204560 ⤷  Free Forever Trial
>Country >Patent Number >Estimated Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Express Scripts
Dow
Harvard Business School
Johnson and Johnson
Merck
Medtronic

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.